<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04327232</url>
  </required_header>
  <id_info>
    <org_study_id>Monitor-AF</org_study_id>
    <nct_id>NCT04327232</nct_id>
  </id_info>
  <brief_title>Mineralocorticoid Antagonism to Stop Progression of Atrial Fibrillation (MONITOR-AF) Study</brief_title>
  <official_title>Mineralocorticoid Antagonism to Stop Progression of Atrial Fibrillation (MONITOR-AF) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Otago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposal details the implementation of an international (Singapore and New Zealand)
      multi-centre study to test a novel therapeutic strategy aimed at reducing the burden of
      atrial fibrillation - an important medical condition with major healthcare implications.
      Unique aspects of this study include i) a non-arrhythmic treatment target (mineralocorticoid
      receptor antagonism) -targeting the arrhythmogenic substrate of AF before it becomes
      permanently established, ii) the use of pacemaker monitoring capability to accurately
      document AF burden, thus increasing the power of the study and iii) multi-national
      collaborative, double blind design.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of persistent AF (defined as the first episode of sustained AF lasting for more than 7 days)</measure>
    <time_frame>18 months</time_frame>
    <description>Development of persistent AF (defined as the first episode of sustained AF lasting for more than 7 days)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of total time in AF.</measure>
    <time_frame>18 months</time_frame>
    <description>Percentage of total time in AF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of AF episodes</measure>
    <time_frame>18 months</time_frame>
    <description>Number of AF episodes &gt; 5 minutes duration recorded on pacemaker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of symptomatic AF episodes</measure>
    <time_frame>18 months</time_frame>
    <description>Number of symptomatic AF episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of admissions for AF</measure>
    <time_frame>18 months</time_frame>
    <description>Number of admissions for AF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LA volumes in millimetre</measure>
    <time_frame>18 months</time_frame>
    <description>Change in LA volumes in millimetre assessed by echo scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LV volumes in millimetre</measure>
    <time_frame>18 months</time_frame>
    <description>Change in LV volumes in millimetre assessed by echo scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic and diastolic function</measure>
    <time_frame>18 months</time_frame>
    <description>Change in systolic and diastolic function assessed by echo scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac and systemic markers</measure>
    <time_frame>18 months</time_frame>
    <description>Change in cardiac and systemic markers of stretch assessed by biomarkers blood tests - NT-proBNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac and systemic markers of inflammation</measure>
    <time_frame>18 months</time_frame>
    <description>Change in cardiac and systemic markers of inflammation assessed by biomarkers blood tests - hsCRP, myeloperoxidase, ST-2, GD-15, Galectin-3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac and systemic markers of fibrosis</measure>
    <time_frame>18 months</time_frame>
    <description>Change in cardiac and systemic markers of fibrosis assessed by biomarkers blood tests - PIIP, type 1 and II procollagen</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For patients randomized to active experimental arm: Spironolactone
Patient will receive study drug for 18 months. Study drug dosages are 1 tablet alternate day, 1 tablet per day, or 2 tablets per day, with 1 tablet being 25mg spironolactone. Study drugs are titrated every 3 months based on patients' potassium and eGFR blood tests results.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>For patients randomized to control arm: Placebo
Patient will receive placebo for 18 months. Placebo dosages are 1 tablet alternate day, 1 tablet per day, or 2 tablets per day. Placebo are titrated every 3 months based on patients' potassium and eGFR blood tests results.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone 25mg</intervention_name>
    <description>Mineralocorticoid Receptor Antagonists</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 21 years (without child-bearing potential for women);

          -  With a permanent pacemaker capable of AF monitoring;

          -  Device documented AF in the last 12 months; Defined as:

             i. atrial high rate events (AHRE) &gt; 220 bpm for &gt;1% of the time; or ii. &gt; 6 mins on at
             least one occasion

        Exclusion Criteria:

          -  Persistent (defined as sustained AF lasting continuously for 7 or more days)

          -  History of heart failure with indication for MRAs

          -  Any existing clinical indication for MRA or K+ sparing diuretic such as uncontrolled
             hypertension or oedema

          -  Contraindication to MRA

          -  Severe renal dysfunction (eGFR &lt;30ml/min by CKD-Epi)

          -  Sustained hyperkalaemia (defined as K+ &gt;5mmol/L in the absence of reversible cause)

          -  Receiving AF suppression pacing

          -  Women of child bearing potential

          -  Patients taking medications which may interact with the study drug or increase the
             level of potassium in the blood, include lithium, amiloride, cyclosporine, eplerenone,
             tacrolimus, and triamterene.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pipin Kojodjojo</last_name>
    <phone>(+65) 67725286</phone>
    <email>pipin_kojodjojo@nuhs.edu.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pipin Kojodjojo</last_name>
      <email>pipin_kojodjojo@nuhs.edu.sg</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wee Kian Kenny Tan</last_name>
      <email>Kenny_WK_TAN@ttsh.com.sg</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vern Hsen Tan</last_name>
      <email>tan.vern.hsen@singhealth.com.sg</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ng Teng Fong General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>609606</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pipin Kojodjojo</last_name>
      <email>pipin_kojodjojo@nuhs.edu.sg</email>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

